Methyl-β-Cyclodextrin Complexation: A Strategy to Improve Ketoprofen Bioavailability and Therapeutic Efficacy

Introduction

Ketoprofen (KTP), a widely prescribed nonsteroidal anti-inflammatory drug (NSAID), suffers from limited aqueous solubility, which restricts its bioavailability and therapeutic efficacy. Moreover, gastrointestinal side effects and dose-dependent toxicity further complicate its oral administration. To address these shortcomings, cyclodextrin-based inclusion complexation has emerged as a rational strategy to enhance the solubility and pharmacokinetics of poorly water-soluble drugs. In this context, researchers [1] investigate the complexation of ketoprofen with methyl-β-cyclodextrin (Mβ-CD), a hydrophilic and biocompatible cyclodextrin derivative, aiming to augment its dissolution rate, improve anti-inflammatory and anti-arthritic efficacy, and ensure safety in potential pharmaceutical formulations.

Solubility and Dissolution Profile

The formation of the KTP–Mβ-CD complex (prepared at a 1:1 molar ratio) significantly improved the aqueous solubility of ketoprofen. Dissolution studies performed under simulated gastrointestinal conditions showed a markedly increased dissolution rate for the complex, achieving approximately 100% drug release within 60 minutes, in contrast to less than 40% release from the pure drug even after 120 minutes. These findings underscore the superior solubilizing capability of methyl-substituted β-cyclodextrin derivatives, which are known to provide enhanced aqueous compatibility and stronger inclusion complex stability than native or hydroxypropyl-substituted counterparts[1].

In Vivo Anti-Inflammatory and Anti-Arthritic Efficacy

The pharmacological efficacy of the inclusion complex was evaluated using established rodent models of inflammation and arthritis. In the carrageenan-induced paw edema model, the KTP–Mβ-CD complex exhibited significantly greater inhibition of paw swelling relative to unformulated ketoprofen, reflecting enhanced acute anti-inflammatory activity. Similarly, in the cotton pellet-induced granuloma model, the complex reduced granuloma weight more effectively, indicating potent chronic anti-inflammatory action.

To assess disease-modifying anti-rheumatic potential, the complex was further tested in a Complete Freund's Adjuvant (CFA)-induced arthritis model. The KTP–Mβ-CD complex achieved substantial attenuation of arthritic symptoms, including reductions in paw thickness, arthritic scores, and histopathological inflammation. The improved in vivo performance is attributed to increased systemic availability arising from improved solubilization and absorption kinetics.

Safety and Biocompatibility Considerations

Methyl-β-cyclodextrin is recognized for its favorable safety profile and has been widely accepted as a pharmaceutical excipient for oral delivery systems. Unlike native β-CD, which may pose nephrotoxicity risks in parenteral applications, Mβ-CD exhibits low toxicity, high water solubility, and minimal membrane irritation. The inclusion complexation approach not only minimizes the required dose of ketoprofen but may also reduce gastrointestinal side effects by modulating drug release and absorption, thereby improving the therapeutic index.

With expertise in cyclodextrin-based formulation development, Alfa Chemistry provide high-quality cyclodextrin-related compounds tailored to pharmaceutical needs. Contact us today to explore custom solutions for your formulation challenges.

Related Products

It should be noted that our our products and services are for research use only, not for clinical use.